Figure 5.
Therapeutical efficacy of SI-10 (6p) in LNCaP xenograft mice model. (A) Tumor growth curve and (B) survive curve of SCID mice with LNCaP xenograft tumors treated by SI-10 (6p). SI-10 (6p) significantly inhibits tumor growth in LNCaP xenograft model and extend survival of SCID mice. LNCaP cells (1×107 cells per mouse) were inoculated into both side under the back skin of SCID mice (male, 4–5 weeks). Treatment started 4 weeks after tumor inoculation. The treatment group was treated with SI-10 (10 mg/kg, i.p.) once per day for 4 weeks (n = 10). The control group was treated with vehicle (n = 11). Tumor volumes were measured once per week. (C) IHC for Ki67, cleaved caspase 3 and CD31 was performed with LNCaP xenograft tumors collected from SI-10 (6p) or vehicle treated mice. Positive cell numbers and microvascular structures were counted and shown in the bar graph. For each marker examined, eight tumor samples from eight mice were included. At least five different areas were counted under microscope for each tumor sample. Data represent mean ± SEM; **p < 0.05, ***p < 0.005.